Research and Development

Assay Development

Renovo has a team of highly trained research personnel engaged in diversifying current assays and developing new assays that can revolutionize neural therapies.

Drug Development

Renovo Neural has exclusive rights to compounds and methods of promoting oligodendrocyte precursor cell differentiation, covered by PCT application PCT/US09/63720.  Renovo is investigating and developing the compounds listed in the application above to generate pharmaceutical lead candidates for potential remyelination therapies.

For more information, please contact info@renovoneural.com.